Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion
Diabetologia · 2026-09 · 69 (9) · 2534-2553
DOI: 10.1007/s00125-026-06779-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, online erschienen am 25.06.2026. Verfasst von Chiara Saponaro und 28 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, Inserm, CHU Lille, U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France. Hauptthemen laut MEDLINE: Liraglutide, Islets of Langerhans, Insulin Secretion, Hypoglycemic Agents. Die Arbeit nennt 82 Literaturangaben. Gefördert von: European Genomic Institute for Diabetes (to VP, FP, and BS), European Research Council Synergy Grant (to VP, RN, and MS), European Foundation for the Study of Diabetes/Lilly-2016 to CB.
Abstract (Originalsprache)
AIMS/HYPOTHESIS: Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist for type 2 diabetes and obesity management, shows variable patient responses. We investigated the metabolic state-dependent mechanisms underlying this heterogeneity and how liraglutide's mode of action shifts across stages of metabolic dysfunction. METHODS: We employed human pancreatic islets from donors across metabolic states (normoglycaemic [HbA1c
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Lille, Inserm, CHU Lille, U1190, European Genomic Institute for Diabetes, Institut Pasteur de Lille, Lille, France.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR_S 1172, European Genomic Institute for Diabetes, Lille, France.
- Blizard Institute, Queen Mary University of London, London, UK.
- Division of Diabetes, Endocrinology and Metabolism, Section of Investigative Medicine, Imperial College London, London, UK.
- Inserm U1220, Institut de Recherche en Santé Digestive (IRSD), International Research Project (IRP), NeuroMicrobiota Lab, CHU Purpan, Toulouse, France.
Förderung
- European Genomic Institute for Diabetes (to VP, FP, and BS)
- European Research Council Synergy Grant (to VP, RN, and MS)
- European Foundation for the Study of Diabetes/Lilly-2016 to CB
- H2020-MSCA Grant (to MI)
- I-SITE ULNE (to VP, FP, and BS)
Zitieren
APA
Saponaro, C., Imbernon, M., Louvet, I., Deligia, E., Chen, S., Davies, I., Acosta-Montalvo, A., Moreno-Lopez, M., Wemelle, E., Kothegala, L., Porteiro, B., Auger, F., Zubiaga, L., Dellalau, N., Thevenet, J., Mühlemann, M., Pasquetti, G., Gmyr, V., Pfrieger, F. W., …, & Bonner, C. (2026). Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion. Diabetologia, 69(9), 2534-2553. https://doi.org/10.1007/s00125-026-06779-2
Vancouver
Saponaro C, Imbernon M, Louvet I, Deligia E, Chen S, Davies I, et al. Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion. Diabetologia. 2026;69(9):2534-2553. doi:10.1007/s00125-026-06779-2
BibTeX
@article{Saponaro2026,
author = {Saponaro, Chiara and Imbernon, Monica and Louvet, Isaline and Deligia, Eleonora and Chen, Shiqian and Davies, Iona and Acosta-Montalvo, Ana and Moreno-Lopez, Maria and Wemelle, Eve and Kothegala, Lakshmi and Porteiro, Begoña and Auger, Florent and Zubiaga, Lorea and Dellalau, Nathalie and Thevenet, Julien and Mühlemann, Markus and Pasquetti, Gianni and Gmyr, Valery and Pfrieger, Frank W and Nogueiras, Ruben and Schwaninger, Markus and Rorsman, Patrik and Staels, Bart and Kerr-Conte, Julie and Knauf, Claude and Jones, Ben and Pattou, François and Prevot, Vincent and Bonner, Caroline},
title = {Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion},
journal = {Diabetologia},
year = {2026},
volume = {69},
number = {9},
pages = {2534--2553},
doi = {10.1007/s00125-026-06779-2}
}
EUVIMED